<?xml version="1.0" encoding="UTF-8"?>
<p>Another prominent repositioned drug is Sildenafil, a phosphodiesterase type 5 inhibitor developed by Pfizer, which was initially intended to treat angina, a condition characterised by chest pain and discomfort due to underlying heart disease where one or more coronary arteries are blocked or narrowed. Sildenafil works by relaxing the coronary arteries to improve coronary blood flow. However, it opened up possibilities for the treatment of erectile dysfunction when several volunteers experienced a strong, unusual persistent erection upon Sildenafil consumption [
 <xref rid="B55-viruses-12-01058" ref-type="bibr">55</xref>]. With further studies and trials carried out, Sildenafil had whopping annual sales of $1.88 billion in the U.S. alone. Today, Sildenafil is widely available over the counter. It works primarily as a treatment for erectile dysfunction via the same mode of action by inhibiting phosphodiesterase type 5 AND preventing the breakdown of cyclic guanosine monophosphate (cGMP), a blood flow regulator in the penis. As of 2019, according to GoodRx, Pfizerâ€™s Viagra still manages to capture a staggering 65% market share even after its loss in exclusive rights on the drug in 2017. 
</p>
